Ikena Oncology Inc. (IKNA) Appoints Richard Wooster to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Ikena Appoints Richard Wooster, Ph.D., to its Board of Directors
January 26, 2022 7:00 AM ESTBOSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, Ikena), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced the appointment of Richard Wooster, Ph.D., to its Board of Directors. Dr. Wooster brings more than 30 years of experience in oncology drug discovery and development and dissecting the genetics of cancer and will provide invaluable insight to Ikena as the Company progresses several programs to benefit patients with difficult-to-treat cancers.
Richards deep research experience and passion for understanding the genetics of cancer and developing new first-in-class targeted oncology therapies makes him an... More
